Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis

https://ift.tt/Ij3XSgP

 

from Sanofi - Aventis Groupe https://ift.tt/rdPcjkR
via IFTTT